IDX184 drug shows efficacy against HCV: Idenix reports
IDX184 is an unpartnered, novel, liver-targeted nucleotide prodrug of 2′-methyl guanosine, and is currently being developed under a partial clinical hold. The randomized, double-blind parallel group Phase IIb
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.